These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1325427)

  • 1. Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma.
    Shirai Y; Kawata S; Ito N; Tamura S; Takaishi K; Kiso S; Tsushima H; Matsuzawa Y
    Jpn J Cancer Res; 1992 Jul; 83(7):676-9. PubMed ID: 1325427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases.
    Shirai Y; Kawata S; Tamura S; Ito N; Tsushima H; Takaishi K; Kiso S; Matsuzawa Y
    Cancer; 1994 May; 73(9):2275-9. PubMed ID: 7513247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma.
    Ito N; Kawata S; Tamura S; Shirai Y; Kiso S; Tsushima H; Matsuzawa Y
    Cancer Lett; 1995 Feb; 89(1):45-8. PubMed ID: 7882301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma.
    Lee D; Chung YH; Kim JA; Lee YS; Lee D; Jang MK; Kim KM; Lim YS; Lee HC; Lee YS
    Oncology; 2012; 82(1):11-8. PubMed ID: 22269311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis.
    Divella R; Daniele A; Gadaleta C; Tufaro A; Venneri MT; Paradiso A; Quaranta M
    Anticancer Res; 2012 Jan; 32(1):141-5. PubMed ID: 22213299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma.
    Okumoto K; Hattori E; Tamura K; Kiso S; Watanabe H; Saito K; Saito T; Togashi H; Kawata S
    Liver Int; 2004 Feb; 24(1):21-8. PubMed ID: 15101997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
    Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
    Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma.
    Ali MA; Koura BA; el-Mashad N; Zaghloul MH
    Egypt J Immunol; 2004; 11(1):83-90. PubMed ID: 15724390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma.
    Ito N; Kawata S; Tamura S; Takaishi K; Shirai Y; Kiso S; Yabuuchi I; Matsuda Y; Nishioka M; Tarui S
    Cancer Res; 1991 Aug; 51(15):4080-3. PubMed ID: 1649698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma.
    An Y; Gao S; Zhao WC; Qiu BA; Xia NX; Zhang PJ; Fan ZP
    World J Gastroenterol; 2018 Jul; 24(25):2733-2740. PubMed ID: 29991878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis.
    Yuen MF; Norris S; Evans LW; Langley PG; Hughes RD
    Scand J Gastroenterol; 2002 Feb; 37(2):233-8. PubMed ID: 11843063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum markers for fibrosis and plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis.
    Murawaki Y; Ikuta Y; Nishimura Y; Koda M; Kawasaki H
    J Gastroenterol Hepatol; 1996 May; 11(5):443-50. PubMed ID: 8743916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
    Yeh YC; Tsai JF; Chuang LY; Yeh HW; Tsai JH; Florine DL; Tam JP
    Cancer Res; 1987 Feb; 47(3):896-901. PubMed ID: 2433030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
    Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
    Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
    Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
    El Bassuoni MA; Talaat RM; Ibrahim AA; Shaker OT
    Egypt J Immunol; 2008; 15(1):39-50. PubMed ID: 20306668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
    Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
    Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
    Li Q; Liu G; Shao D; Wang J; Yuan H; Chen T; Zhai R; Ni W; Tai G
    Int J Biochem Cell Biol; 2015 Feb; 59():116-25. PubMed ID: 25526895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.
    Malfettone A; Soukupova J; Bertran E; Crosas-Molist E; Lastra R; Fernando J; Koudelkova P; Rani B; Fabra Á; Serrano T; Ramos E; Mikulits W; Giannelli G; Fabregat I
    Cancer Lett; 2017 Apr; 392():39-50. PubMed ID: 28161507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.
    Wittmann P; Grubinger M; Gröger C; Huber H; Sieghart W; Peck-Radosavljevic M; Mikulits W
    BMC Cancer; 2015 Nov; 15():909. PubMed ID: 26573807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.